Press review & News
Here you can find the latest news about Italfarmaco and the international press reviews.
Press review
The material contained in this section is intended for informational purposes only and is not promotional. This section is intended for journalists and media.
2025 – Oct 20
ITALFARMACO
Italfarmaco and Istituto Ronzoni Announce BioSpecNet, a Scientific Consortium: First Private 800 MHz NMR in Italy to Support Rare Disease Research
2025 – Oct 9
ITALFARMACO
Italfarmaco Appoints Francesco Di Marco as Chief Executive Officer
2025 – Oct 7
ITALFARMACO
New Data Presented on Givinostat for Treatment of Duchenne Muscular Dystrophy at 2025 World Muscle Society Congress
2025 – July 11
ITALFARMACO
Italfarmaco Presents New Cardiac Data for Givinostat at 16th European Paediatric Neurology Society (EPNS) Congress
2025 – June 6
ITALFARMACO
European Commission Approves Duvyzat for the Treatment of Duchenne Muscular Dystrophy
2025 – May 6
GlobeNewswire
Italfarmaco Announces U.S. FDA Grants Fast Track Designation to Givinostat in Treatment of Polycythemia Vera
May 6, 2025 - GlobeNewswire
Please kindly note that you are leaving Italfarmaco Group website to connect to another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with the current Italian legislation.
2025 – April 28
ITALFARMACO
CHMP recommends EU approval for Duvyzat to treat Duchenne muscular dystrophy
2025 – March 6
Business Wire
Italfarmaco Provides Overview on Givinostat as Treatment for Duchenne Muscular Dystrophy: Progress in Global Access, Regulatory Milestones and Clinical Trials
March 6, 2025 - Business Wire
Please kindly note that you are leaving Italfarmaco Group website to connect to another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with the current Italian legislation.
2024 – March 21
Business Wire
Italfarmaco Receives FDA Approval for Duvyzat™ (givinostat) in Duchenne Muscular Dystrophy
March 21, 2024 - Business Wire
Please kindly note that you are leaving Italfarmaco Group website to connect to another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with the current Italian legislation.
2024 – March 19
Business Wire
Italfarmaco Publishes in The Lancet Neurology results from Phase 3 EPIDYS Study in Duchenne Muscular Dystrophy (DMD)
March 19, 2024 - Business Wire
Please kindly note that you are leaving Italfarmaco Group website to connect to another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with the current Italian legislation.
2023 – September 05
Business Wire
Italfarmaco Group Receives EMA Validation of Marketing Authorization Application for Givinostat in Duchenne Muscular Dystrophy
September 05, 2023 - Business Wire
Please kindly note that you are leaving Italfarmaco Group website to connect to another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with the current Italian legislation.
2023 – June 29
Business Wire
Italfarmaco Group Completes FDA Submission of New Drug Application for Givinostat in Duchenne Muscular Dystrophy and Receives Priority Review
June 29, 2023 - Business Wire
Please kindly note that you are leaving Italfarmaco Group website to connect to another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with the current Italian legislation.
2022 – June 25
Business Wire
Italfarmaco Group Announces Positive Topline Data from Phase 3 Trial Showing Beneficial Effect of Givinostat in Patients with Duchenne Muscular Dystrophy
June 25, 2022 - Business Wire
Please kindly note that you are leaving Italfarmaco Group website to connect to another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with the current Italian legislation.
News
2024 - June 28
Combines AI to increase the potential of novel histone deacetylase (HDAC) inhibitors in the non-oncological field
2023 - September 7
7 September marks World Duchenne Awareness Day (WDAD), a disease in which we as a company are particularly involved.
2022 - September 7
September 7th is World Duchenne Muscular Dystrophy Awareness Day, a disease that sees us, as a company, at the forefront of the search for a drug that can slow down its progression.
2022 - July 26
Thanks to this operation, that is subject to the approval of the competition authorities, the Group will reach 1,300 employees in Spain and 3,500 globally, with a consolidated turnover of over 1 billion euros.
2020 - September 7
World Duchenne Awareness Day represents a great action of the global Duchenne Community to raise awareness for children and young adults living with Duchenne and Becker Muscular Dystrophy. This year the special theme that deserves more attention is “Duchenne and the brain”.
2020 - June 26
"Donnenmd" is a project promoted by the pediatric area of the NeMO Center in Rome, in collaboration with the Agostino Gemelli University Hospital Foundation IRCCS with the aim of providing training and information on some neuromuscular pathologies with childhood onset and to enhance the experiences of affected and caregivers women.
